Astrazeneca P L C (AZN) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Astrazeneca P L C (AZN)

181.55

-4.40 (2.37%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

108 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

AstraZeneca PLC (AZN-N) has shown robust performance with a 30% increase in the past year, buoyed by a booming oncology business and a strong product pipeline projected to generate significant revenue. Experts highlight the company’s innovative approach, particularly in oncology, which has exceeded expectations. Although some predict a slight pullback to the $85 mark, the overall sentiment remains positive, emphasizing the company's strong fundamentals since 2017-18. Analysts are optimistic about AstraZeneca's long-term revenue goals, voicing confidence in its ability to reach $80 billion by 2030 with 7% annual growth. The stock's valuation at 15x PE, coupled with a 2% dividend yield, further supports its favorable view among healthcare stocks, especially in comparison to competitors.

Consensus

Bullish

Valuation

Fair Value

Similar

Abbvie,ABBV

DON'T BUY

They produced an early Covid vaccine, but got lost among other vaccines that were more effective. There are better fish to fry. They report Friday.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Apr 06/21, Up 30%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN has achieved its $64 objective. To remain disciplined, we recommend covering half the position here. We continue to recommend holding a stop loss at $56, which if triggered would result in a net investment return over 21% along with today's recommendation of covering half.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Apr 22/21, Up 22.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN is progressing well. We now recommend trailing the stop (from $42) to $56. If triggered, this would all but guarantee a net investment return of 13%.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly AZN is the COVID-19 vaccine producer that has been granted emergency use authorization in over 50 countries. It also has one of the best pipelines for new biotech drugs. They just acquired a strategic company that will further "boost" their immunology presence. The company pays a good dividend that is projected to have a payout ratio under 75% of cash flow next year. The company is estimated to have added over $2.3 billion to its cash reserves, which are now over $7.5 billion. We would buy this with a stop loss at $42, looking to achieve $64 -- upside potential of 28%. Yield 2.83% (Analysts’ price target is $63.73)

BUY ON WEAKNESS

Allan Tong’s Discover Picks The AZN stock currently trades at a 64x PE and pays a not-bad 2.69% dividend yield. It's trending $7 below its $59.73 price target, and has declined slightly to June levels. However, its PE has tumbled to levels last seen in December 2019. Three analysts rate it a strong buy, one a buy and another a hold, unchanged since August. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.

COMMENT

Their Covid vaccine in progress For most of the large-cap pharmas he owns, the benefits of producing this vaccine won't benefit these companies as much as people think. That said, AZN has been executing very well in areas like oncology--a key driver for them. In May, AZN's vaccine was his front runner in this race. AZN (with Oxford University) did have a negative reaction during their recent phase 3 test, though, so there is a risk here. However AZN has resumed tests outside the U.S., so expect results a little later. So now Pfizer has become the front runner. He's looking for the safety profile of AZN's candidate. If their vaccine is a miss, there will be stock volatility, but also a buying opportunity. A great company.

Premium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

Paul McDonald also recommends GSK's peer, AstraZeneca (also trading in New York and London). The pharma is focusing on its pipeline of drugs that can't be easily replicated. A third of its sales comes from the U.S., plus 20% from China, which may actually be a tailwind in this context. The New York stock (AZN-N) pays a 2.87% dividend and the London one pays 2.95%

BUY

They have done what Pfizer is in the process of doing. They focused in on their pipeline with drugs that are difficult to replicate. Their immunotherapy drug has been doing well, and the chart looks great. The fundamentals of the business is good. Multiples are around 13x though one of the best EPS. He is generating good premiums on his positions.

HOLD

One of their perfect pharma holdings with well diversified and global holdings. It trades at a slight premium to the peer group, but that is warranted as it specializes in oncology. The company on has 33% of sales from the US which shelters itself somewhat from the politics of pharma. 20% of revenues come from China (where growth is 30% per year).

HOLD

AZN has a very deep phase-3 pipeline of drugs being tested and tried. The growth won't kick in until 2021-3. He loves their dividend. They've been shedding assets to focus on less price-sensitive areas. Earnings are 16x, going down to 14x in 2020. This will be a lighter quarter, because they aren't selling as many assets, but he's happy to own this.

HOLD

New oncology drugs. No problems owning it. If you're going to be in the pharma sector, buy one stock only. In the sector, half are up, and half are down. Yield is 3.3% and still growing, though not hugely.

PAST TOP PICK

(A Top Pick Dec 11/17, Up 30%) They'd been struggling for years, but developed a bunch of new drugs. He thinks this will rise a lot higher.

PAST TOP PICK

(A Top Pick December 11/17 - Up 18%) The whole health care sector heated up over the last year. Very safe stock to hold. Nice dividend.

PAST TOP PICK

(A Top Pick May 10/17, Up 16%) It's a diversified biopharma out of the UK. Surprised many by annoucning phase 2 drug trial in lung cancer--a frontrunner in this space. Their main drivers is their immunotherapy business. A great growth profile in the industry, but need to execute on a few of these trials in the next 6-12 months. Own it with BMY-N and MRK-N and not alone.

TOP PICK

Has an impressive line of new products that should hit the market over the next 10 years, in cancer, diabetes and Alzheimer’s. They have underperformed for the last several years, and now is starting to turn the corner. Dividend yield of 4.28%. (Analysts’ Price Target is $38.)

Showing 31 to 45 of 52 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Astrazeneca P L C (AZN)